MESO · Mesoblast Limited American Depositary Shares
Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
Follow MESO by emailGet an email when MESO pushes back a promised milestone, files for a stock offering or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about MESO, unsubscribe in one click. Privacy
📣 What MESO Says Is Next
Q4 · “Expected duration 18 months, with interim analysis expected Q4 CY2027 for potential early success Potential Market for RYONCIL Label Extension as Part of Second-line Regimen Combined with Ruxolitinib in Adults with Grade III/IV aGvHD Interim analysis planned for early success when first 102 patients (57% enrolled) have reached Day 28 (primary endpoint) Analysis expected Q4 CY2027 57% 16 Jess, this is the commercial section – per our call:”
Company press release, Aug 27, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Get the full MESO picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for MESO and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.